Patents by Inventor W. H. Kerr Anderson

W. H. Kerr Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Plant production of immunoglobulins with reduced fucosylation
    Patent number: 8106169
    Abstract: This invention provides for the plant production of immunoglobulins, wherein at least a portion of the glycans attached to the immunoglobulins lack fucose. The invention also provides the constructs; plasmids; vectors; transformed plant cells, transformed plant calli; transformed plant tissues (e.g., leaves, seeds, tubers, etc.); transformed whole plants used to produce such immunoglobulins; methods of producing the immunoglobulins; the immunoglobulins produced by the disclosed methods; and the use of such immunoglobulins.
    Type: Grant
    Filed: November 28, 2003
    Date of Patent: January 31, 2012
    Assignee: Phyton Holdings, LLC
    Inventors: Kristen Briggs, Todd Glancy, Mich B. Hein, Andrew C. Hiatt, Anton S. Karnoup, W. H. Kerr Anderson, Dayakar Pareddy, Joseph Petolino, Beth Rubin-Wilson, Doug Taylor, Jean L. Roberts
  • USES OF CATIONIC HYDROXYETHYLCELLULOSE IN ORAL INGESTION FORMS, AND PREVENTION AND TREATMENT OF METABOLIC DISORDERS
    Publication number: 20100331278
    Abstract: Described are an oral ingestion form comprising cationic hydroxyethylcellulose, and methods of using the same in prevention and treatment of metabolic disorders.
    Type: Application
    Filed: May 6, 2010
    Publication date: December 30, 2010
    Inventors: W. H. Kerr Anderson, Shao-Ching Hung, William T. Stott, Maciej Turowski, Wallace H. Yokoyama, Scott A. Young
  • High affinity humanized anti-tag-72 monoclonalantibodies
    Patent number: 6753152
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: June 22, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonal antibodies
    Patent number: 6752990
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: June 22, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-Tag-72 monoclonal antibodies
    Patent number: 6753420
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: June 22, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonal antibodies
    Patent number: 6737060
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: May 18, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonal antibodies
    Patent number: 6737061
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: May 18, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • Probing method for identifying antibodies specific for selected antigens
    Patent number: 6641999
    Abstract: This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal VH and VL sequences which mediate TAG-72 binding and (2) human CH and CL regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human CH and CL antibody domains. The nucleotide and amino acid sequences of VH&agr;TAG VH, CC46 VH, CC49VH, CC83 VH, and CC92 VH, and CC49VL, CC83 VL, and CC92 VL idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: November 4, 2003
    Assignee: The Dow Chemical Company
    Inventors: Peter S. Mezes, Brian Gourlie, Mark W. Rixon, W. H. Kerr Anderson
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20030027994
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: February 6, 2003
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20030018171
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: January 23, 2003
    Inventors: W.H Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Publication number: 20030013854
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: January 16, 2003
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Publication number: 20030013856
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: January 16, 2003
    Inventors: W.H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-tag-72 monoclonalantibodies
    Publication number: 20030004318
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: January 2, 2003
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-tag-72 monoclonalantibodies
    Publication number: 20020193574
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: December 19, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Publication number: 20020183497
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: December 5, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20020183495
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: December 5, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20020165387
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: November 7, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Patent number: 6417337
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Grant
    Filed: February 18, 1998
    Date of Patent: July 9, 2002
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Patent number: 6348581
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: February 18, 1998
    Date of Patent: February 19, 2002
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Patent number: 6333405
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: December 25, 2001
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour